Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition comprising protein phosphatase 1 inhibitory peptide for treating vascular diseases

A protein phosphatase and vascular disease technology, which is applied in the field of vascular disease therapeutic compositions comprising protein phosphatase 1 inhibitory peptides, and can solve problems such as difficulty in determining the transfer efficacy effect and the like

Active Publication Date: 2019-06-14
贝特基因公司
View PDF7 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this cell-penetrating peptide (CPP) is not derived from human protein sequences, so it contains risks of cytotoxicity and immunogenicity
Also, in the recent clinical results of biopharmaceutical supplements combined with cell-penetrating peptides (CPP), it is difficult to determine the transfer efficacy or cargo effect to human cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition comprising protein phosphatase 1 inhibitory peptide for treating vascular diseases
  • Composition comprising protein phosphatase 1 inhibitory peptide for treating vascular diseases
  • Composition comprising protein phosphatase 1 inhibitory peptide for treating vascular diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0114] 1. Ethics statement

[0115] Animal experiments using Sprague-Dawley rats and C57BL / 6 mice were approved by the Seoul National University Hospital and Ewha Womans University and the Animal Care and Ethics Committee (IACUC) of the Gwangju Institute of Science and Technology, according to the United States. According to the Guidelines for the Care and Use of Laboratory Animals (Press, 8th Edition, 2011) issued by the National Institutes of Health (National Academy). All experiments were performed using 8 week old male Sprague-Dawley rats from Charles River, USA. The environmental conditions were controlled at a temperature of 25±2°C, a relative humidity of 50±5%, and a 12:12-hour light-dark cycle.

[0116] 2. Synthesis of Chemicals and protein phosphatase1 inhibitory peptides

[0117] ΨPLB-SE (RAE16TIEMPQ; second sequence in the Sequence Listing) is derived from the phospholamban (PLB) protein sequence surrounding the Ser16 phosphorylation site. To facilitate intra...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a composition comprising a protein phosphatase 1 inhibitory peptide for treating vascular diseases. The composition of the present invention inhibits protein phosphatase 1 (PP1)-mediated dephosphorylation to suppress abnormal proliferation of vascular smooth muscle cells (VSMCs), and activates eNOS of vascular endothelial cells (VECs) to induce the recovery from dysfunction, and thus can be favorably used in the treatment of vascular diseases including pulmonary hypertension.

Description

technical field [0001] The present invention was completed through the project number GF01330 supported by the Ministry of Future Creation and Science of Korea. The research management professional institution of the above project is the Korean Research Foundation, the name of the research project is "Global Laboratory Project", and the name of the research project is "Heart Research on Signal Transduction and Gene Therapy of Disease", the competent institution is Gwangju Institute of Science and Technology, and the research period is from April 1, 2013 to March 31, 2014. [0002] This patent application claims priority from Korean Patent Application No. 10-2016-0138612 filed with the Korean Patent Office on Oct. 24, 2016, the disclosure of which is incorporated herein by reference. [0003] The present invention relates to a composition for treating vascular diseases comprising a protein phosphatase 1 inhibitory peptide. Background technique [0004] Vascular remodeling ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/08A61P9/00A61P9/10A61P9/12A23L33/18
CPCA23L33/18A61P9/10A61P9/12A61K47/645A23L33/17A61K38/1709C07K14/435C12N9/16A61K38/08A61P9/00A23V2002/00A23V2200/326
Inventor 朴佑镇张胜弼
Owner 贝特基因公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com